You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Atovaquone And Proguanil Hydrochloride patents expire, and what generic alternatives are available?

Atovaquone And Proguanil Hydrochloride is a drug marketed by Glenmark Pharms Ltd and Mylan and is included in two NDAs.

The generic ingredient in ATOVAQUONE AND PROGUANIL HYDROCHLORIDE is atovaquone; proguanil hydrochloride. There are sixteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the atovaquone; proguanil hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Atovaquone And Proguanil Hydrochloride

A generic version of ATOVAQUONE AND PROGUANIL HYDROCHLORIDE was approved as atovaquone; proguanil hydrochloride by GLENMARK PHARMS LTD on January 12th, 2011.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE?
  • What are the global sales for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE?
  • What is Average Wholesale Price for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE?
Summary for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
Drug patent expirations by year for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
Recent Clinical Trials for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The 108 Military Central HospitalPhase 4
Australian Defence Force Malaria and Infectious Disease Institute (ADF MIDI)Phase 4
Naval Medical Research Unit TWO (NAMRU-2)Phase 4

See all ATOVAQUONE AND PROGUANIL HYDROCHLORIDE clinical trials

Pharmacology for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

US Patents and Regulatory Information for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glenmark Pharms Ltd ATOVAQUONE AND PROGUANIL HYDROCHLORIDE atovaquone; proguanil hydrochloride TABLET;ORAL 091211-002 Apr 6, 2015 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan ATOVAQUONE AND PROGUANIL HYDROCHLORIDE atovaquone; proguanil hydrochloride TABLET;ORAL 202362-002 May 27, 2014 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Glenmark Pharms Ltd ATOVAQUONE AND PROGUANIL HYDROCHLORIDE atovaquone; proguanil hydrochloride TABLET;ORAL 091211-001 Jan 12, 2011 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan ATOVAQUONE AND PROGUANIL HYDROCHLORIDE atovaquone; proguanil hydrochloride TABLET;ORAL 202362-001 May 27, 2014 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.